Cystic Fibrosis Study
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects with Cystic Fibrosis and the G551D Mutation
Protocol ID
09-10-102
Protocol Description
The purpose of this study is to see if an experimental drug called VX-770 can help decrease some of the effects of cystic fibrosis (CF). This study is also being done to learn more about the safety and effects of VX-770 on CF patients.
Eligibility Criteria
People with cystic fribrosis (CF)
Primary Investigator(s)
- Rubin Cohen, MD